Abstract-The purpose of this article is to provide researchers, clinicians, and policymakers with a com-
INTRODUCTION
DRUG ABUSE policy debates often begin with discussions about the total cost of drug abuse to society. This question has sparked the interest of so many government policy officials that several agencies within the Department Practitioners frequently ask economists and other social scientists who study drug abuse interventions about cost and benefit issues: How do I estimate the costs of my program? How do I estimate the outcomes and dollar benefits of my program? Is it possible to examine the benefit--cost implications of my program with a modest amount of time and money? The answers to these questions depend on a variety of factors, but program evaluators typically can begin to examine economic issues if they have a catalogue of existing economic data. Economic data related to substance abuse consequences and costs are not voluminous, nor can the information be found in a single source. Although all of the quantitative information presented in this article can be found in other studies, it has been organized here in an accessible and userfriendly resource guide, thereby increasing its utility and reducing search costs.
We have organized the costs of potential drug abuse consequences into nine broad categories for clarity and exposition--medical services costs; perinatal costs; drug abuse treatment costs; drug-associated diseases costs; cost of alcohol, illicit drug, and mental health (ADM) comorbidity; crime-related costs; foster care payments; special education and early intervention costs; and costs of Aid to Families with Dependent Children (AFDC) including food stamps. Some of these categories are not immediately recognized as a cost of drug abuse per se, but drug-related consequences can certainly extend into all of these areas. Furthermore, we chose cost categories for which quantitative economic data are available. Thus, the categories are not collectively exhaustive of all potential drug abuse consequences, but represent a broad sample of the types of costs associated with drug abuse. Lastly, the benefits of drug abuse interventions derive from the avoided costs of drug-related consequences, so these cost estimates can be combined with program outcomes to estimate the dollar benefits of drug abuse interventions. We do not include a formal presentation of economic evaluation methods in this article because these techniques are carefully explained in several other sources (e.g., Drummond, Stoddart, & Torrance, 1987; French, 1995; French, Zarkin, & Bray, 1995; Hu, McDonnell, & Swisher, 1981; Zarkin, French, Anderson, & Bradley, 1994) .
The quantitative economic information reported here should have significant clinical, policy, and research value for policymakers and researchers who frequently request economic cost and benefits data. In addition, policymakers can use the estimates presented here as a "fact sheet" to guide future economic evaluations. As evaluators require new and different economic data, this information can be updated to reflect these emerging needs. Evaluation information such as the cost estimates presented in this article will help advance the art of program evaluation in the drug abuse field and lead to more rigorous and comparable economic findings.
RESEARCH METHODS
We used several sources to identify the appropriate literature for this analysis. Our starting point was the substance abuse literature collected for studies completed by Research Triangle Institute (RTI) staff since the early 1980s. Most of these studies relied exclusively on primary data compiled by RTI. Some studies examined the societal costs of substance abuse (Harwood et al., 1984) while others estimated specific costs (Bradley, French, & Rachal, 1994) For instance, French and his colleagues [1996 (a) ] examined the economic costs of different modalities of drug treatment, while Rajkumar and French (in press ) developed estimates of societal crime costs. Our examination of the reports prepared by RTI enabled us to determine precisely what costs were captured by these studies, allowing a better comparison with other research studies.
We also used RTI's extensive library of substance abuse literature, which provided us with a good sense of the types of information readily available in the literature. We compiled a list of journals, researchers, and key words with which to begin our on-line searches.
We conducted literature searches using several article indexes, including MedLine, Uncover, and the Expanded Academic Index, and electronic card catalogs, principally those of the University of North Carolina at Chapel Hill, North Carolina State University, and Duke University. Although none of these sources is independently comprehensive, combining them provides reasonable coverage of published articles and books.
We used the bibliographies of the articles we located as sources of additional literature to search for seminal research studies. We also used the Social Science Citation Index to locate manuscripts that cited articles we had already located.
Inclusion Criteria
We were unable to include all of the potential substance abuse cost information in our analysis. An understanding of the criteria used to determine which information to include is useful both for researchers wishing to expand on this study and for those trying to use our information directly.
We constrained our research to categories in which estimated cost elements were available and judged to be reasonably accurate. We excluded some costs of substance abuse that are not well documented from our analysis. In addition, we excluded estimates of total societal costs of substance abuse because this information is widely reported (e.g., Crnze et al., 1981; Harwood et al., 1984; Rice, Kelman, & Miller, 1991) We concentrated our efforts on estimates of specific consequences.
The above discussion highlights the information intentionally omitted from our analysis. Some information may have been unintentionally excluded. For example, special reports completed under contract with government agencies and corporations are often unpublished and thus not listed in databases. Our only sources for these articles were personal contacts and bibliographies of manuscripts. In addition, because our main sources of articles were on-line databases, the thoroughness of our search is subject to their accuracy. Last, we may have overlooked certain information that is important to some evaluators. We attempted to mitigate this problem by giving several researchers the opportunity to comment and augment earlier drafts. We encourage other researchers to help improve the coverage of this analysis during future updates, eventually providing a more complete body of cost estimates for substance abuse consequences.
Comparability
The studies cited in our analysis cover more than a decade of research. To compare estimates, the financial values must be adjusted to a base-year equivalent. We selected 1994 as our base year and used various consumer price indexes (CPIs) published by the Bureau of Labor Statistics (BLS) for our inflators.
The reliability of using the CPI for certain types of costs is uncertain. Because the CPI uses a "basket of goods" method to determine the inflation adjustment for each sector of the economy, it tends to inflate overall costs better than specific items. In industries with low price growth, the difference between the industry rate and that of specific sectors may be small. However, in industries where prices rise rapidly the difference can be dramatic. These differences are exacerbated if the overall inflation rate is driven by factors, such as technology changes, that affect the industry unevenly. In particular, we found the medical services CPI to be an inadequate inflator for neonatal intensive care unit (NICU) costs. Consequently, we developed a unique multiplier for perinatal care, which is described later.
RESULTS
To make our information accessible, we report our findings in a series of summary tables, organized by cost categories. In most cases, each of the costs we estimated fit neatly into a broader category. For instance, inpatient hospital costs fit well with medical services costs, and the cost of special education fit well into the category of early childhood intervention. However, in a few cases, the cost elements did not match any particular category, yet did not merit a new category. Overall, we feel that individual cost estimates are easily organized within certain cost categories and the number of categories can be expanded as new estimates become available. Table 1 for evaluation purposes, the researcher or clinician must know the magnitude of the changes in medical services utilization. Once the change in service use is known, the clinician can multiply the number of units saved by the average cost per unit to estimate the medical service cost savings of the intervention.
Medical Services Costs
The original source of the emergency room episode is the National Medical Care Expenditure Survey, and the cost of the emergency room episode is an average of all emergency room costs. Unfortunately, a range is not available. We suspect that the average cost reported in the survey is affected by the number of nonemergency visits. These visits have lower costs relative to visits requiring extensive medical intervention. Therefore, using our cost estimate for intervention cohorts who use emergency room services primarily for life-threatening emergencies will lead to downward-biased cost estimates. Obviously, if the cohort is homogenous relative to the general population, the average cost estimate will be fairly reliable.
Finally, we decided to include prenatal care and pregnancy prevention in the medical services costs. The cost given for prenatal care includes maternity and prenatal care up to 60 days post delivery; actual delivery costs are excluded but average around $3,020 (Long, Marquis, & Harrison, 1994) . Pregnancy prevention includes one annual physician visit and a 12-month supply of birth control pills.
Perinatal Care
For the purposes of this article, we define perinatal as the time period from conception to 1 year after birth. The traditional period starts when the fetus attains 500 grams and ends after 28 days of neonatal life. We have extended the period to capture prenatal care and first-year morbidity costs. Table 2A outlines the cost differences between infants of normal birth weight, low birth weight, and very low birth weight. These estimates are useful for programs trying to estimate the benefits of targeting birth weight in an intervention. The costs listed here are first-year perinatal costs (excluding delivery costs) distributed by birth weight. To use these numbers, a program must know the percentage of infants born in each weight category. For instance, consider using the cost data in Table 2A for total costs through the first year. If an at-risk group typically has 60% normal birth weight children, 30% low birth weight, and 10% very low birth weight, the current cost per 100 births is approximately $1,896,250. Assuming that all 100 births were normal weight infants, the total cost would amount to $933,000. If an intervention is implemented that leads to a new distribution of 70% normal birth Miller, and Dunmeyer (1990) . fDerived from fiscal year 191 Medicaid claims for Massachusetts. QGrannemann and Brown (1986). h Hellinger (1993) . 'Lessard, Harrison, and Hoffman (1985) . JArno, Sherson, Seigel, Franks, and Lee (1989). kAnderson, Galinis, and Bowland (1994) . 'Jacobs (1995) . r" Long, Marquis, and Harrison (1994) . °lficludes maternity and prenatal care up to 60 days post-delivery. Delivery costs are excluded. °Reis (1991). 0Includes one physician visit per year and a 12-month supply of birth control. qHsia, Fleishman, East, and Hellinger (1995) . 'Holtgrave and Quails (1995) .
[Note: This analysis does not include pain and suffering. sConviser, Young, and Grant (1991). tAndrulis, McGregor, Weiss, Ramirez, Ginsberg, and Shaw-Taylor (1995) . UHellinger, Fleishman, and Hsia (1994) . v Bennett, Pascal, Cvanic, Graham, Kitchens, and DeHovitz (1992) . WBozzette, Parker, and Hay (1994) .
weights, 25% low birth weights, and 5% very low birth weights, the new cost per 100 births would be $1,553,385 --a cost reduction of $342,865 from the preintervention condition.
It should be noted that Tables 2A and 2B define very low birth weight as all births below 1,500 grams, but this range does not actually include infants with birth weights below 500 grams. Infants with birth weights below 500 McCormick (1985) . qnitial hospitalization after delivery. These numbers do not include rehospitalization.
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grams are not considered medically viable in the sense that medical resources are not used for their support. These infants have a subsequent mortality rate of 100 percent, and the only applicable medical costs are prenatal and delivery. Table 2B outlines the NICU costs for infants of different birth weights. The data in Tables 2A and 2B overlap because NICU costs are implicitly included as a portion of the costs presented in Table 2A . Table 2B is included in our analysis because it provides explicit NICU costs and excludes other perinatal costs. NICU costs are important because even a short stay in a NICU significantly increases neonatal costs. Infants born in low birth weight categories who do not use NICU facilities have lower costs than infants using NICUs. Therefore, facilities with high NICU demand as well as programs trying to isolate particular NICU resources in their program costs can use these estimates. Table 2B illustrates the potential bias of using the standard inflation adjustment measures for specialized medical services. Schwartz's (1989) research is a welldocumented source of costs that agree in other aspects with the costs outlined in contemporary articles (Phibbs, Bateman, & Schwartz, 1991) . The problem occurs when trying to inflate costs to 1994 levels. When converted to 1994 dollars using standard adjustment factors, Schwartz's estimates are significantly less than the costs reported in recent sources. They average less than $9,000 per week while The New York Times estimated NICU costs to be greater than $14,000 dollars per week in 1991 (The New York Times, 1991) and cost data from the Texas Tech University Health Science Center (TTU HSC) (Martin, 1995) in Lubbock, Texas, estimated an average weekly cost in excess of $13,902 in 1994. Therefore, to adequately inflate Schwartz's numbers, we used her estimate for all NICU costs in 1986 and the TTUHSC estimate for all NICU costs in 1994 to develop a better multiplier. By dividing the costs found at the TTUHSC for 1994 by Schwartz's 1985-86 numbers, we derived a multiplier of 5.9. We then used this multiplier to inflate Schwartz's cost estimates for each birth weight category. While this approach is not perfect, we believe it yields a better approximation of the inflation-adjusted value than the estimate derived using the medical services CPI. The BLS lists several different medical CPIs; however, these different CPIs are very similar to one another. Therefore, using a different CPI would not have corrected the potential adjustment problem. Schwartz (1989) . bMultiplier developed by Martin (1995) . Note: The costs given here are Schwartz's NICU costs inflated to 1994 dollars. Because the medical services CPI did not inflate the NICU costs adequately, we used the costs derived from the Texas Tech University Health Science Center (TTUHSC) (Martin, 1995) to derive a multiplier to inflate the costs. Using the NICU costs at the TTUHSC from January 1994 to January 1995, TTUHSC researchers found the average cost of a day in NICU to be $1,986. We used this number divided by Schwartz's average daily cost for all NICU patients to derive a multiplier of 5.9. We then used this multiplier to covert the costs given for particular birth weights to 1994 levels. Table 2C outlines additional costs associated with maternal drug use. Phibbs, B ateman, and Schwartz (1991) and Joyce et al. (1995) estimated the marginal cost of intrauterine drug exposure. Both studies examined cocaine use, drugs other than cocaine, and cocaine plus other drugs, and both studies used New York hospital data. Yet, the adjusted costs and length of stay in Phibbs, Bateman, and Schwartz (1991) are approximately 50% greater than those found by Joyce et al. (1995) . We decided to use the costs from Joyce et al. (1995) for two reasons. First, Joyce and his colleagues use more recent data, which lessens the inflation problem discussed earlier. Second, they provide seemingly more conservative estimates of the costs. Table 3 presents the economic costs for three different modalities of drug treatment. Many studies quote costs for different modalities of drug treatment, but we included only studies that examined the economic (i.e., opportunity) costs of drug treatment. Also, because we had several good sources for this category, we tended to use studies that contained the most detail about data collection strategies and research methods so that costs could be easily compared. Table 4 reports the full morbidity costs (i.e., including the cost of pain, suffering, distress, and other intangible elements) associated with a set of diseases and health conditions. The items listed here are diseases and conditions that are particularly exacerbated by substance abuse or that a substance abuser is more likely to contract than a member of the general population. French et al. [1996 (b) ] use a multiattribute quality-adjusted life-year (QALY) methodology to calculate these figures. The framework is based on developing a common unit of well-being that can be applied to all types of health conditions. An explanation of the QALY technique for benefit estimation is beyond the scope of this paper. For a thorough explanation, see French et al. [1996 (b) ], Bleichrodt (1995) , or Tolley, Kenkel, and Fabian (1994) . OThe severity and staging information for this condition was adapted primarily from Hellinger (1993). The estimated value of avoiding only the premature mortality (exclusive of the morbidity) caused by AIDS is equal to $2,497,119 (5% discount rate) for a white male who contracts HIV at age 32 and dies prematurely at age 44. Table 5 presents the additional length of stay and cost for a person with alcohol, drug, or mental health (ADM) comorbidity. The average cost per case is derived by using the inflated estimated average daily cost per hospital day for a person with ADM comorbidity (Rice, Kelman, & Miller, 1991) . We multiplied the additional length of stay by the daily cost to find the average per-case cost. The additional length of stay calculated here is based on average lengths of stay for 1985, and because the average length of stay for all persons has increased slightly from 7. l days in 1985 to 7.2 days in 1991 (American Hospital Association, 1992), average length of stay for persons with ADM comorbidity may have increased slightly as well. French (in press)--that use primarily secondary data to estimate their crime-specific costs. Rajkumar and French outline the specific costs for crime victims and the criminal justice system, as well as crime career costs. For this reason, we use their costs for all categories except for rape and murder, which they did not examine. Both Miller, Cohen, and Rossman (1993) and Rajkumar and French (in press ) used the jury compensation method to estimate intangible costs. Neither article includes property loss in their calculations. CReflects an additional length of stay multiplied by the cost of an average overnight hospital stay. These costs are a lower-bound average because many people with ADM comorbidity may require additional specialty services that are not included in the average daily cost. alncludes medical costs, lost wages, reduced productivity, property damage, risk of homicide, pain and suffering, and psychological costs. blncludes the costs of police protection, running the criminal justice system, private legal costs, drug trafficking, and correctional facilities. °Value of lost productivity of law-abiding citizens who turn to crime rather than pursue a lawful career. dThese numbers are the sum of crime victim costs (including intangible elements), criminal justice system costs, and crime career costs. eThis category is defined as rape when the victim is injured and also includes attempted rapes when victim injury occurred. fMiller, Cohen, and Rossman (1993). These authors describe three categories of costs: direct losses other than property losses; productivity losses including wages, fringe benefits, and housework; and nonmonetary losses including pain, suffering, and lost quality of life. To calculate the nonmonetary costs of injury they used the jury compensation and the willingness-to-pay methods. g Rajkumar and French (in press ). These authors calculated intangible costs for aggravated assault and robbery using the jury-compensation method. This approach imputes the cost of pain and suffering for each type of crime-related injury using jury awards in cwil cases where the medical expenses and lost wages are known. even in the form of average payments. Therefore, to report total payments, we used the federal payments to calculate the state payment levels. We were able to make this calculation because the federal payments are based on the state payments. The federal government portion of foster care payments ranges from 50% to 80% of the state payment. Although the exact percentage paid to each state is not readily available, the average federal payment per child is compiled in the federal Green Book (U.S. House of Representatives, 1993) . Using the federal payment and the above percentages, we were able to calculate minimum and maximum possible state payments. We calculated the maximum and the minimum possible state payment by dividing the average federal foster care payment by 0.50 and 0.80, respectively. We then summed the calculated minimum and maximum state payments with the federal payments to derive a minimum and maximum possible foster care payment for each category. Finally, to derive our average aU.S. House of Representatives (1993) . bThese figures represent the additional cost of specialized foster care above the average minimum and maximum basic foster care payments from Table 7A .
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payment for children in foster care in the United States, we took an unweighted average of the minimum and maximum state payments. Table 7B details the additional costs of specialized foster care. As we discussed briefly above, the cost of providing foster care varies according to the specific needs of the foster child. For some children, the additional needs are fairly minimal. For instance, a child with behavioral problems may only need foster parents who have been educated in dealing with behaviorally difficult children. Children with other types of disabilities may need to be placed in therapeutic foster care.
The federal Green Book (U.S. House of Representatives, 1993) describes the additional costs of each of these types of foster care. To calculate the additional cost, we first derived a baseline cost of basic family foster care from Table 7A by averaging the minimum and maximum costs over all age groups. We then used this number as a baseline price for basic family foster care and subtracted it from the total cost of each type of specialized care. These estimates are rough averages and the exact cost will vary depending on the actual needs of the child and family.
A driving factor in the total cost of foster care is the length of time a child is kept in foster care. Because the factors that influence foster care length of stay are documented, they can be used to predict the costs of foster care for a particular child whose risk factors are known. These factors as well as their corresponding lengths of stay are outlined in Table 7C .
These length of stay medians should be used with care because we suspect that the actual cases in foster care are not uniformly distributed. In fact, because many children are placed in foster care for long periods of time (Albers, Reilly, & Rittner, 1993) and other children are placed in foster care for very short periods of time (e.g., children who have lost their parents through a traumatic event and are only in foster care long enough to identify a relative), this implies a bimodal distribution. aChaikind, Danielson, and Brauen (1993) . bAverage per-pupil expense for disabled child's education. This number includes both special education expenses and the portion of regular educational expenses used by disabled pupils (i.e., if the child spends part of the day in a regular classroom). cCost per disabled pupil minus the costs of education for nondisabled pupils. Table 8A shows the average costs of special education programs for children with disabilities. The per-child cost varies tremendously depending on the needs and disabilities of the child. Costs range from over $41,695 per year for students with deaf-blindness to $1,083 per year for students with speech disabilities (Chaikind, Danielson, & Brauen, 1993) . Additionally, because costs are primarily a function of the pupil-teacher ratio, high-incidence disabilities tend to be less expensive than low-incidence disabilities.
Early Childhood Intervention Costs
In Table 8A , average annual cost refers to the total cost per child for the school program (e.g., preschool, residential). This estimate is useful for capturing the full costs of a program, but it is not necessarily the cost that should be used when estimating the burden of drug use per se. For estimating additional costs of drug abuse that may lead to disability, the excess annual cost should be used. The cost estimates in the second column of Table  8A represent the incremental costs for a disabled pupil relative to a nondisabled student in the same modality. Table 8B displays the different expected costs of early intervention for children with varying levels of need. For the purposes of this table, we provide the costs of intervention for children with families that are able to provide basic social, economic, emotional, and health needs. Hall et al. (1993) consider family needs an important factor in the cost of an intervention. For this analysis, we have omitted the extra costs of family need. Instead, we chose to highlight the costs explicit to the child's needs. Note that the costs are higher for families with high levels of need and lower for families that can provide more than basic levels of support. Still, the primary factor driving the cost of the intervention is the child's level of need. Children needing medically intensive interventions have higher expected intervention costs than children with low levels of need, regardless of family need. aHall, Stone, Walsh, Wager, Hakes, and Graham (1993) . bAssumes the child has multiple medical problems and developmental delays that have often been environmentally induced and that require extensive medical support. CAssumes the child has two or more established conditions or multiple biological risks accompanied by emotional problems and developmental delays. dAssumes the child has significant health and/or developmental problems including sensory impairments stemming from a physically or neurologically compromising illness or trauma. ~Assumes the child has congenital and/or neurological problems with a visible developmental delay. fAssumes one or two biological risk factors are present in the child's history such as very low birth weight. gHall et al. (1993) assume that the normal family is able to provide basic social, economic, emotional, and health needs. Furthermore, they assume the family only needs services as they pertain to the risk factor of the child. Having a higher or lower level of family need will affect he cost of the intervention. Policy, 1993) .
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APPLICATION
An application of these estimates to a hypothetical intervention will help demonstrate how the information presented in these tables can be used. For example, suppose a city planning board is trying to decide whether or not to expand the number of beds available for a publicly supported drug treatment program. The board has already conducted a pilot study of a similar expansion in another program and wishes to find out if the expansion can be economically justified. The pilot study consisted of a 100-bed expansion. The planning board already knows that the expansion will cost taxpayers approximately $1.5 million annually. Based on initial outcomes data from the pilot project, client records, and data from external agencies, the planning board wants to estimate the preliminary dollar benefits of the expansion. Table 10 illustrates the changes that are expected to occur before and after the expansion in economic terms. The column labeled "Size of Reduction" in Table 10 represents the number of consequences (e.g., cases, crimes, diseases) for each outcome category. The next column, "Savings per Unit of Reduction," corresponds to the information reported in our earlier tables. Multiplying the size of reduction by the savings per unit reduction results in an estimated total savings for each category (last column of Table 10 ). The sum of the total savings for each outcome category in Table 10 yields an estimate for the expected total savings of the expansion--S1,947,025. Recall that the total cost of this representative intervention was $1,500,000, resulting in a net savings of $447,025.
Although the numbers in Table 10 are not to be taken literally, they do illustrate the type of analysis that can be performed. Rather than trying to estimate net benefits for every evaluation, program planners can now rely on the estimates reported in this study to identify the total and net savings of their intervention. They can also compare the size of the savings from particular interventions with other interventions they may be considering to help allocate resources efficiently.
DISCUSSION
Strengths and Limitations
The primary contribution of this analysis is the easy accessibility to information on substance abuse consequences and related costs in a single document. Most of the information contained in our summary tables has been published in peer-reviewed journals, and the remainder of the information has been compiled by various search methods. We have attempted to tabulate and present this information in one source in an effort to significantly reduce the data gathering and research time required by evaluators and clinicians to estimate the costs and benefits of drug abuse interventions. All of the information presented in this article is abstracted from other research projects: no primary data collection was performed expressly for this study.
Another strength of this analysis is the methods used to "normalize" cost data from a variety of sources. Although researchers debate the virtues of averaging estimates from different sources, studies such as ours can eliminate some of the individual bias found in single studies (Mann, 1994) . Also, some studies have insufficient data points to make their estimates generally appli- aEqual to the cost for a very low birth weight infant ($64,027) minus the cost for a normal birth weight infant ($9,330). bEqual to the cost for a low birth weight infant ($23,206) minus the cost for a normal birth weight infant ($9,330).
cable, but when their estimates are consistent with other studies that have estimated similar costs, either with or without sufficient data points, the cost estimates are more credible. Despite the volume of information reported, our analysis is still limited by the quality and availability of data. In several of the areas for which we estimate costs, only a few good sources of information exist. In some of these cases, the sources that we did locate were rigorous in their methodologies and they examined cost information from a large and representative sample of sources [e.g., Chaikind, Danielson, & Brauen, 1993; ]. In other cases, the sources containing reliable cost estimates were not necessarily generalizable to other programs (Van Stelle, Mauser, & Moberg, 1994) . In these cases, we decided not to report the findings, preferring instead to report cost estimates that would be useful to a broader audience.
Although substance abuse research is currently an active field, some of the major economic studies done in this area tend to use cost information that is fairly dated (e.g., Phibbs, Bateman, & Schwartz, 1991; Rice et al., 1991) . As a result, some of the costs presented in our analysis are from data sources that are as much as 10 years old. For comparability purposes, we inflated all of the costs reported in our analysis to 1994 dollars. With the exception of neonatal intensive care, we used the appropriate CPI as given by the U.S. Bureau of Labor Statistics. However, even the most specific CPIs combine a large number of goods and services. Therefore, some of the inflators we used may have been inadequate for inflating specific cost elements.
Finally, the characteristics of substance-abusing populations have changed significantly over the last 10 years (Coleman, 1993) . Contemporary substance users are experimenting with different types of drugs, and the strength of drugs previously in wide use may have increased, changing the net effect on the user (Pitts, O'Neil, & Leggo, 1990) . At the same time, infectious diseases such as HIV and tuberculosis have become more common among substance-abusing populations. These changes lead to differences in both the direct and indirect costs of treating individual substance abusers and alter the overall societal costs as well. However, the information presented in this article provides a solid foundation for the costs of individual substance abuse consequences, and this research can be expanded as more data become available.
It should also be noted that we used unweighted averages of the available estimates throughout the study. Therefore, because some studies have many more data points than others, our averages may be disproportionally influenced by studies with fewer data points. Consequently, our average cost estimates may need to be weighted as additional data become available.
Significance and Policy Implications
This study is significant in that it is the first attempt to form a unified source of substance abuse costs for specific cost elements. Although all of the estimates presented in this analysis have been previously published or reported, the estimates have been scattered throughout a variety of sources. Each source that estimated costs did so only for the categories relevant to their purpose. We have attempted to provide a more comprehensive presentation of cost estimates.
Policy makers proposing an intervention that is likely to have a particular impact on the substance abusing population will have a source for estimating the likely costs and benefits of the intervention. Clinicians who conducted an intervention may have had difficulty convincing funding sources of the benefits of their program. They may have been able to estimate the changes in behavior resulting from their intervention, but were unsure how to place convincing dollar values on the cost savings. Now, once they have modeled the magnitude of the changes, they have a source for cost estimates.
Once policymakers are able to attach believable and consistent dollar benefits to interventions, they will then be able to directly compare the benefits and costs of alternative programs. In this manner, they will be able to choose the appropriate intervention while balancing costs and benefits with available resources.
FUTURE DIRECTION
This analysis is not meant to be a finished product. Rather, we intend to periodically update estimates of the costs of substance abuse consequences so that clinicians and researchers have current estimates of the economic costs and benefits of their programs. The information reported here can be improved in many ways during future enhancements.
The principal way in which this analysis can be improved, without further primary research, is through expansion. Because we attempted to present a general overview of the costs of many aspects of substance abuse, we were unable to provide all of the information available in each category. Therefore, the study can be greatly expanded in each area by outlining more of the specific costs that we left implicit in each category (e.g., the cost of the counselor's time in drug treatment or per-diem prison costs). In addition, we did not provide cost estimates in other areas that might be of interest to clinicians. An analysis concentrating on these areas would be a valuable addition to this study. However, the most significant improvements require primary data collection and more focused research.
In the past, the lack of organization of cost information has created difficulties in determining exactly which areas lack good cost estimates. Our analysis has highlighted several areas where cost information is either incomplete or nonexistent. Now that the gaps have been highlighted, a significant barrier has been removed from obtaining estimates of these other costs. Future economic research can address these areas.
Finally, the analysis can be improved by finding better ways of comparing the costs across studies. Comparing dollar amounts as we have done here is convenient, but costs vary from one part of the country to another and from one time period to another. Further, as discussed earlier, the available inflators are not always adequate for inflating prices from one year to another. This may be especially true for areas in which the prices tend to increase fairly rapidly. For instance, medical services as a category has increased in cost at rates far higher than other aspects of the economy. However, the increase is not uniform and one of the driving factors behind these increases is varying levels of reliance on technologic improvements. A subdivision of medical services that relies more heavily on technology than others (e.g., neonatal intensive care units) will have higher inflation rates. Therefore, for some categories of costs, nonmonetary comparisons may be more appropriate than monetary comparisons.
